A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with CLL who are Intolerant to Prior BTK or PI3K Inhibitor Therapy

Drug Category: Array
Conference Category: Array
Lead Author: Mato A, et al.
Published Date: 04/06/2018
Download Link: /wp-content/uploads/2025/09/Final-2018-TKI-ASCO.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top